Seres Therapeutics is a microbiome therapeutics company headquartered in Cambridge, Massachusetts and was founded in 2010 by Noubar Afeyan and David Berry. Seres Therapeutics is using a discovery and design platform for developing new therapies using live bacteria for the treatment of diseases that are a result of microbiome deficiencies. Seres Therapeutics is focused on developing therapies for the treatment of Clostridium difficile infection (CDI), inflammatory bowel disease, and an oral microbiome therapy for improving the safety and efficacy of immunotherapies.
On November 27, 2012 Seres Therapeutics closed their series A funding round with an undisclosed amount of funding from Flagship Pioneering and Enso Ventures.
On may 23, 2014 Seres Therapeutics closed their series B funding round with$10 million in funding from Mayo Clinic, Flagship Pioneering, Enso ventures, and Alexandria Venture.
On December 2, 2014 Seres Therapeutics closed their series C funding round with $48 million in funding from Flagship Pioneering.
On January 6, 2015 Seres Therapeutics closed their series D funding round with $65 million in funding from Nestlé Health Science.
Timeline
People
Barbara McGovern
Vice President, Medical Affairs
Carlo Tanzi
Vice President, Investor Relations and Corporate Communications
Carol Lewis-Cullinan
Vice President, Clinical Operations
David Berry
Co-Founder
David Cook
Executive Vice President, CSO
Eric Shaff
Executive Vice President, Chief Operating and Financial Officer
Henry Rath
Senior Vice President, Corporate Development
Jeff York
Vice President, Human Resources
Jim Weston
Senior Vice President, Regulatory Affairs
John Aunins
Executive Vice President, Bioprocesses & manufacturing and CTO
Kevin Horgan
Executive Vice President, Chief Medical Officer
Mathew Henn
Executive Vice president, Microbiome Research and Development
Noubar Afeyan
Co-Founder
Roger Pomerantz
President, CEO, and Chairman of the Board of Directors
Thomas DesRosier
Executive Vice President, Chief Legal Officer and Secretary